FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Morgan Bradley Paul 		2. Issuer Name and Ticker or Trading Symbol

CYTOKINETICS INC [ CYTK ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP Drug Discovery & Early Dev
(Last)          (First)          (Middle)

280 EAST GRAND AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/15/2006
(Street)

SOUTH SAN FRANCISCO, CA 94080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy)   $6.0   3/5/2013     A      21204.0       4/5/2013   (1) 3/5/2023   Common Stock   21204   $0.0   21204   D    
Incentive Stock Option (right to buy)   $6.3   3/5/2012     A      13920.0       4/5/2012   (2) 3/5/2022   Common Stock   13920   $0.0   13920   D    
Incentive Stock Option (right to buy)   $6.67   2/23/2016     A      18817.0       3/23/2016   (3) 2/23/2026   Common Stock   18817   $0.0   18817   D    
Incentive Stock Option (right to buy)   $7.96   2/26/2015     A      11044.0       3/26/2015   (4) 2/26/2025   Common Stock   11044   $0.0   11044   D    
Incentive Stock Option (right to buy)   $9.42   2/28/2011     A      11883.0       3/28/2011   (5) 2/28/2021   Common Stock   11883   $0.0   11883   D    
Incentive Stock Option (right to buy)   $9.65   2/24/2014     A      18448.0       3/24/2014   (6) 2/24/2024   Common Stock   18448   $0.0   18448   D    
Incentive Stock Option (right to buy)   $11.1   2/26/2009     A      2638.0       3/26/2009   (7) 2/26/2019   Common Stock   2638   $0.0   2638   D    
Incentive Stock Option (right to buy)   $11.1   2/26/2009     A      2639.0       3/26/2009   (7) 2/26/2019   Common Stock   2639   $0.0   5277   D    
Incentive Stock Option (right to buy)   $18.48   2/24/2010     A      3333.0       3/24/2010   (8) 2/24/2020   Common Stock   3333   $0.0   3333   D    
Incentive Stock Option (right to buy)   $18.48   2/24/2010     A      4278.0       3/24/2010   (9) 2/24/2020   Common Stock   4278   $0.0   7611   D    
Incentive Stock Option (right to buy)   $20.22   2/29/2008     A      2101.0       3/29/2008   (10) 2/28/2018   Common Stock   2101   $0.0   2101   D    
Incentive Stock Option (right to buy)   $40.86   3/14/2007     A      3106.0       4/14/2007   (11) 3/14/2017   Common Stock   3106   $0.0   3106   D    
Incentive Stock Option (right to buy)   $42.24   3/15/2006     A      5000.0       4/1/2006   (12) 3/15/2016   Common Stock   5000   $0.0   5000   D    
Non-Qualified Stock Option (right to buy)   $6.0   3/5/2013     A      3795.0       4/5/2013   (1) 3/5/2023   Common Stock   3795   $0.0   3795   D    
Non-Qualified Stock Option (right to buy)   $6.3   3/5/2012     A      1079.0       4/5/2012   (2) 3/5/2022   Common Stock   1079   $0.0   1079   D    
Non-Qualified Stock Option (right to buy)   $6.67   2/23/2016     A      31183.0       3/23/2016   (3) 2/23/2026   Common Stock   31183   $0.0   31183   D    
Non-Qualified Stock Option (right to buy)   $7.96   2/26/2015     A      18956.0       3/26/2015   (4) 2/26/2025   Common Stock   18956   $0.0   18956   D    
Non-Qualified Stock Option (right to buy)   $9.42   2/28/2011     A      617.0       3/28/2011   (5) 2/28/2021   Common Stock   617   $0.0   617   D    
Non-Qualified Stock Option (right to buy)   $9.65   2/24/2014     A      11552.0       3/24/2014   (6) 2/24/2024   Common Stock   11552   $0.0   11552   D    
Non-Qualified Stock Option (right to buy)   $11.1   2/26/2009     A      695.0       3/26/2009   (7) 2/26/2019   Common Stock   695   $0.0   695   D    
Non-Qualified Stock Option (right to buy)   $11.1   2/26/2009     A      694.0       3/26/2009   (7) 2/26/2019   Common Stock   694   $0.0   1389   D    
Non-Qualified Stock Option (right to buy)   $18.48   2/24/2010     A      721.0       3/24/2010   (9) 2/24/2020   Common Stock   721   $0.0   721   D    
Non-Qualified Stock Option (right to buy)   $20.22   2/29/2008     A      1033.0       3/29/2008   (10) 2/28/2018   Common Stock   1033   $0.0   1033   D    
Non-Qualified Stock Option (right to buy)   $40.86   3/14/2007     A      193.0       4/14/2007   (11) 3/14/2017   Common Stock   193   $0.0   193   D    

Explanation of Responses:
( 1)  When the ISO and NQ dated 03/05/2013 are combined for a total grant of 24,999 shares, the option shall vest and become exercisable as to 520 shares on 04/05/2013 and the balance of 24,479 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/05/2017.
( 2)  When the ISO and NQ dated 03/05/2012 are combined for a total grant of 14,999 shares, the option shall vest and become exercisable as to 312 shares on 04/05/2012 and the balance of 14,687 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/05/2016.
( 3)  When the ISO and NQ dated 02/23/2016 are combined for a total grant of 50,000 shares, the option shall vest and become exercisable as to 50,000 shares divided into equal monthly installments such that the option shall be 100% vested on 02/23/2020.
( 4)  When the ISO and NQ dated 02/26/2015 are combined for a total grant of 30,000 shares, the option shall vest and become exercisable as to 625 shares on 03/26/2015 and the balance of 29,375 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/26/2019.
( 5)  When the ISO and NQ dated 02/28/2011 are combined for a total grant of 12,500 shares, the option shall vest and become exercisable as to 260 shares on 03/31/2011 and the balance of 12,240 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/28/2015.
( 6)  When the ISO and NQ dated 02/24/2014 are combined for a total grant of 30,000 shares, the option shall vest and become exercisable as to 625 shares on 03/24/2014 and the balance of 29,375 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/2018.
( 7)  When the ISO and NQ's dated 02/26/2009 are combined for a total grant of 6,666 shares, the option shall vest and become exercisable as to 138 shares on 03/26/09 and the balance of 6,528 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/26/13.
( 8)  This option shall vest and become exercisable as to 69 shares on 03/24/10 and the balance of 3,264 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/14.
( 9)  When the ISO and NQ dated 02/24/2010 are combined for a total grant of 4,999 shares, the option shall vest and become exercisable as to 104 shares on 03/24/2010 and the balance of 4,895 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/2014.
( 10)  When the ISO and NQ dated 02/29/2008 are combined for a total grant of 3,134 shares, the option shall vest and become exercisable as to 65 shares on 03/29/08 and the balance of 3,069 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/29/12.
( 11)  When the ISO and NQ dated 03/14/2007 are combined for a total grant of 3,299 shares, the option shall vest and become exercisable as to 68 shares on 04/01/07 and the balance of 3,231 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/11.
( 12)  This option shall vest and become exercisable as to 104 shares on 04/01/06 and the balance of 4,896 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/10.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Morgan Bradley Paul
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080

SVP Drug Discovery & Early Dev

Signatures
Bradley Morgan 2/25/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cytokinetics Charts.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cytokinetics Charts.